Experiences with monoclonal antibody therapy for allergic asthma

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

卷:108

Article

Boushey, HA

关键词: asthma;    IgE;    anti-IgE;    amalizumab;    allergic disease;    atopy;   

DOI  :  10.1067/mai.2001.116434

来源: Elsevier

【 摘 要 】

Identification of the central role IgE plays in the pathogenesis of allergic diseases made it a key target for therapy. The first selective anti-I-E therapy, a unique humanized monoclonal anti-IgE antibody (omalizumab), binds with high affinity to the Fc epsilon RI receptor binding site on IgE, thereby reducing the amount of free IgE available to bind to Fc epsilon RI receptors on mast calls, basophils, and other cells. In addition, administration of omalizumab indirectly reduces Fc epsilon RI receptor density on cells involved in allergic responses. In two bronchoprovocation trials involving patients with mild allergic asthma, omalizumab attenuated both early- and late-phase allergic responses. Omalizumab was subsequently evaluated as a treatment for asthma in large, multicenter, randomized, double-blind phase II and III trials involving patients with moderate to severe asthma who required corticosteroid therapy. When added to treatment with oral or inhaled corticosteroids, omalizumab reduced symptoms and exacerbations, improved lung function and quality of life, and reduced the need for rescue medications. These benefits persisted even in the corticosteroid reduction phase of these trials, when omalizumab treatment was shown to allow patients to reduce or discontinue their inhaled and/or oral corticosteroids. These effects of omalizumab in improving asthma control, as NN ell as its excel I ent safety profile, may ultimately make this agent a useful addition to the physician's armamentarium of treatments for asthma.

【 授权许可】

Free